An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Titan Medical to Participate in Upcoming Investor Conferences in September
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Titan Medical Inc. (Nasdaq: TMDI) announced that President and CEO David McNally will present at two investor conferences: the Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on September 21, 2021, and the Cantor Virtual Global Healthcare Conference on September 27, 2021. The company focuses on robotic single access surgery technology, specifically its Enos™ surgical system. Webcasts of the presentations will be available on the company's website.
Positive
None.
Negative
None.
TORONTO--(BUSINESS WIRE)--
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, will present an overview of the company and its Enos™ robotic single access surgical system and participate in one-on-one investor meetings at two upcoming investor conferences:
The Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on Tuesday, September 21, 2021
The Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021
The presentations will be webcast and available on their respective presentation dates and replayed via links on the Investor Relations Events section of the company’s website https://ir.titanmedicalinc.com/news-events/ir-calendar.
About Titan Medical
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company headquartered in Toronto, Ontario and with R&D facilities in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery using innovative technology through a single access point. The Enos™ robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand and includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications. Certain aspects of Titan’s robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system.
This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Such statements reflect the current expectations of management of the company’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: the company’s focus on the design and development of surgical technologies for robotic single access surgery; the company’s intention to initially pursue gynecologic surgical indications with the Enos system; and the license of certain of Titan’s robotic assisted surgical technologies and related intellectual property to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the company’s Annual Information Form and Form 40-F for the fiscal year ended December 31, 2020 (which may be viewed at www.sedar.com and at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Titan Medical Inc. is traded under the stock symbol TMDI.
When will Titan Medical present at investor conferences?
Titan Medical will present at the Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on September 21, 2021, and at the Cantor Virtual Global Healthcare Conference on September 27, 2021.
What is the focus of Titan Medical's Enos™ system?
The Enos™ system focuses on robotic single access surgery, initially targeting gynecologic surgical indications.
How can I access Titan Medical's conference presentations?
The presentations will be webcast and available on Titan Medical's Investor Relations Events section on their website.
What is the purpose of the investor conferences for Titan Medical?
The conferences aim to provide an overview of Titan Medical's innovative surgical technologies and facilitate one-on-one investor meetings.
